Filana Therapeutics, Inc. Other Nonoperating Expense
Filana Therapeutics, Inc. (FLNA) reported Other Nonoperating Expense of $206.00 thousand for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-05-07.
Financial Statements › Income Statement › Other Income
us-gaap:OtherNonoperatingExpense · last filed 2026-05-07
- Filana Therapeutics, Inc. other nonoperating expense for the quarter ending 2026-03-31 was $206.00K, a 5.07% decline year-over-year.
- Filana Therapeutics, Inc. other nonoperating expense for the quarter ending 2025-12-31 was $132.00K, a 11.41% decline year-over-year.
- Filana Therapeutics, Inc. other nonoperating expense for the quarter ending 2025-09-30 was $230.00K, a 1.77% increase year-over-year.
- Filana Therapeutics, Inc. other nonoperating expense for the quarter ending 2025-06-30 was $156.00K, a 27.44% decline year-over-year.
- Filana Therapeutics, Inc. other nonoperating expense for fiscal 2025 was $736.00K, a 11.64% decline from fiscal 2024.
- Filana Therapeutics, Inc. other nonoperating expense for fiscal 2024 was $833.00K, a 39.46% decline from fiscal 2023.
- Filana Therapeutics, Inc. other nonoperating expense for fiscal 2023 was $1.38M, a 5.88% decline from fiscal 2022.
- Filana Therapeutics, Inc. other nonoperating expense for fiscal 2022 was $1.46M, a 206.50% increase from fiscal 2021.
| Period end | Other Nonoperating Expense 3 month | Other Nonoperating Expense 6 month | Other Nonoperating Expense 9 month | Other Nonoperating Expense 12 month | Other Nonoperating Expense 12 month as first filed |
|---|---|---|---|---|---|
| 2026-03-31 | $206.00K 10-Q · filed 2026-05-07 | $338.00K derived: sum of 2 quarters · filed 2026-05-07 | $568.00K derived: sum of 3 quarters · filed 2026-05-07 | $724.00K derived: sum of 4 quarters · filed 2026-05-07 | |
| 2025-12-31 | $132.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $362.00K derived: sum of 2 quarters · filed 2026-03-12 | $518.00K derived: sum of 3 quarters · filed 2026-03-12 | $736.00K 10-K · filed 2026-03-12 | |
| 2025-09-30 | $230.00K 10-Q · filed 2025-11-12 | $386.00K derived: sum of 2 quarters · filed 2025-11-12 | $604.00K 10-Q · filed 2025-11-12 | $752.00K derived: sum of 4 quarters · filed 2026-05-07 | |
| 2025-06-30 | $156.00K 10-Q · filed 2025-08-14 | $374.00K 10-Q · filed 2025-08-14 | $522.00K derived: sum of 3 quarters · filed 2026-05-07 | $748.00K derived: sum of 4 quarters · filed 2026-05-07 | |
| 2025-03-31 | $217.00K 10-Q · filed 2026-05-07 | $366.00K derived: sum of 2 quarters · filed 2026-05-07 | $592.00K derived: sum of 3 quarters · filed 2026-05-07 | $807.00K derived: sum of 4 quarters · filed 2026-05-07 | |
| 2024-12-31 | $149.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $375.00K derived: sum of 2 quarters · filed 2026-03-12 | $590.00K derived: sum of 3 quarters · filed 2026-03-12 | $833.00K 10-K · filed 2026-03-12 | $832.00K 10-K · filed 2025-03-03 |
| 2024-09-30 | $226.00K 10-Q · filed 2025-11-12 | $441.00K derived: sum of 2 quarters · filed 2025-11-12 | $684.00K 10-Q · filed 2025-11-12 | $977.00K derived: sum of 4 quarters · filed 2026-03-12 | |
| 2024-06-30 | $215.00K 10-Q · filed 2025-08-14 | $458.00K 10-Q · filed 2025-08-14 | $751.00K derived: sum of 3 quarters · filed 2026-03-12 | $1.11M derived: sum of 4 quarters · filed 2026-03-12 | |
| 2024-03-31 | $243.00K 10-Q · filed 2025-05-08 | $536.00K derived: sum of 2 quarters · filed 2026-03-12 | $896.00K derived: sum of 3 quarters · filed 2026-03-12 | $1.25M derived: sum of 4 quarters · filed 2026-03-12 | |
| 2023-12-31 | $293.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $653.00K derived: sum of 2 quarters · filed 2026-03-12 | $1.01M derived: sum of 3 quarters · filed 2026-03-12 | $1.38M 10-K · filed 2026-03-12 | |
| 2023-09-30 | $360.00K 10-Q · filed 2024-11-07 | $716.00K derived: sum of 2 quarters · filed 2024-11-07 | $1.08M 10-Q · filed 2024-11-07 | $1.51M derived: sum of 4 quarters · filed 2025-03-03 | |
| 2023-06-30 | $356.00K 10-Q · filed 2024-08-08 | $723.00K 10-Q · filed 2024-08-08 | $1.15M derived: sum of 3 quarters · filed 2025-03-03 | $1.56M derived: sum of 4 quarters · filed 2025-03-03 | |
| 2023-03-31 | $367.00K 10-Q · filed 2024-05-10 | $797.00K derived: sum of 2 quarters · filed 2025-03-03 | $1.21M derived: sum of 3 quarters · filed 2025-03-03 | ||
| 2022-12-31 | $430.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | $840.00K derived: sum of 2 quarters · filed 2025-03-03 | $1.46M 10-K · filed 2025-03-03 | ||
| 2022-09-30 | $410.00K 10-Q · filed 2023-11-07 | $1.03M 10-Q · filed 2023-11-07 | |||
| 2021-12-31 | $477.00K 10-K · filed 2024-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 |